Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway Sells 9,926 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 9,926 shares of the stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.00, for a total transaction of $287,854.00. Following the completion of the transaction, the senior vice president now directly owns 187,258 shares in the company, valued at $5,430,482. The trade was a 5.03% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Artivion Price Performance

Shares of Artivion stock opened at $28.41 on Friday. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $32.33. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -1,420.25 and a beta of 1.54. The company has a fifty day moving average of $25.05 and a 200-day moving average of $27.36. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $98.98 million during the quarter, compared to analysts’ expectations of $94.81 million. Equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Citizens Jmp raised shares of Artivion to a “strong-buy” rating in a report on Tuesday, May 6th. Stifel Nicolaus decreased their price target on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 25th. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Artivion in a report on Tuesday, May 6th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $31.40.

Institutional Investors Weigh In On Artivion

Institutional investors have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its position in Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock valued at $32,000 after buying an additional 786 shares during the period. Legacy Advisors LLC purchased a new stake in Artivion during the 1st quarter valued at $28,000. MCF Advisors LLC boosted its position in Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after buying an additional 614 shares during the period. R Squared Ltd purchased a new stake in Artivion during the 4th quarter valued at $39,000. Finally, Arcadia Investment Management Corp MI purchased a new stake in Artivion during the 4th quarter valued at $43,000. Hedge funds and other institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.